Aller au contenu principal
Profil bibliographique

Matthew J. Lawes

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

22Publications signalées
1156Citations signalées
0Affiliations récentes

Les domaines associés

Macrophage Migration Inhibitory FactorChronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia ResearchNuclear Receptors and SignalingChronic Myeloid Leukemia Treatments

Les publications récentes

Accès ouvert 2024 article OpenAlex

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, Richard James Dillon et autres

PURPOSE To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. PATIENTS AND METHODS One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard …

gb, dk, nz (code pays fourni par la source)

47 citations Journal of Clinical Oncology
Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figures 1 and 2 and Supplementary Tables 1 and 2 from MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia

Amina M Abdul-Aziz, Manar S. Shafat, Tarang K. Mehta, Federica Di Palma et autres

This file contains Supplementary Figures and Tables. Supplementary Figure 1 shows long term survival of AML on BM-MSC. Supplementary Figure 2 shows the combinations of AML and BM-MSC co-cultures. Supplementary Table 1 shows AML patient information and Supplementary table 2 shows BM-MSC …

0 citations
Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figures 1 and 2 and Supplementary Tables 1 and 2 from MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia

Amina M Abdul-Aziz, Manar S. Shafat, Tarang K. Mehta, Federica Di Palma et autres

This file contains Supplementary Figures and Tables. Supplementary Figure 1 shows long term survival of AML on BM-MSC. Supplementary Figure 2 shows the combinations of AML and BM-MSC co-cultures. Supplementary Table 1 shows AML patient information and Supplementary table 2 shows BM-MSC …

0 citations
2022 article OpenAlex

The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom

Christopher J. Saunders, Chandan Kumar Saha, Priya Sriskandarajah, Helen Cashman et autres

Background: Advanced systemic mastocytosis (AdvSM) is a rare haematological neoplasm occurring due to clonal proliferation of mast cells in extracutaneous organs. In up to 95% of cases, the driver mutation is KIT D816V. AdvSM encompasses aggressive SM (ASM), mast cell leukaemia and …

gb (code pays fourni par la source)

1 citation Blood
2019 conference-abstract OpenAlex

Acute Myeloid Leukemia Export Mitochondria in Extracellular Vesicles Which Induces Pro-Tumoral Changes in Bone Marrow Macrophages

Jamie A Moore, Jayna J. Mistry, Rebecca H. Horton, Charlotte Hellmich et autres

It is envisioned that improved understanding of the dependency of acute myeloid leukemia (AML) on its tumour microenvironment within the bone marrow could be exploited to offer new treatment strategies and better patient outcomes. Previously we have shown that the bone marrow …

gb (code pays fourni par la source)

1 citation Blood
2017 conference-abstract OpenAlex

Abstract 4327: Bone marrow adipocytes drive transcriptional changes in leukemic blasts to enhance their capacity to derive energy from free fatty acid metabolism

Manar S. Shafat, Thomas Oellerich, Sebastian Mohr, Stephen D. Robinson et autres

Abstract Introduction: Most patients diagnosed with acute myeloid leukaemia [AML] die of their disease and the average age of patients at diagnosis is 72 years. For this reason, new therapeutic strategies with tolerability in the fragile, less fit population is necessary for …

gb, de (code pays fourni par la source)

1 citation Cancer Research
Accès ouvert 2017 article OpenAlex

Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment

Manar S. Shafat, Thomas Oellerich, Sebastian Mohr, Stephen D. Robinson et autres

Despite currently available therapies, most patients diagnosed with acute myeloid leukemia (AML) die of their disease. Tumor-host interactions are critical for the survival and proliferation of cancer cells; accordingly, we hypothesize that specific targeting of the tumor microenvironment may constitute an alternative …

gb, de (code pays fourni par la source)

340 citations Blood
2016 article OpenAlex

Hypoxia Drives AML Proliferation in the Bone Marrow Microenvironment Via Macrophage Inhibitory Factor

Amina M Abdul-Aziz, Manar S. Shafat, Lyubov Zaitseva, Matthew J. Lawes et autres

Abstract Introduction Hypoxia is an important component of the bone marrow microenvironment and the hematopoietic stem cell niche. Studies have shown that hypoxia contributes to the development and maintenance of acute myeloid leukemia (AML) cells within the bone marrow microenvironment. Hypoxia is …

gb (code pays fourni par la source)

1 citation Blood
Accès ouvert 2016 article OpenAlex

MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia

Amina M Abdul-Aziz, Manar S. Shafat, Tarang K. Mehta, Federica Di Palma et autres

Acute myeloid leukemia (AML) cells exhibit a high level of spontaneous apoptosis when cultured in vitro but have a prolonged survival time in vivo, indicating that tissue microenvironment plays a critical role in promoting AML cell survival. In vitro studies have shown …

gb (code pays fourni par la source)

90 citations Cancer Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.